Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
OTCMKTS
· Delayed Price · Currency is USD
65.44
0.00 (0.00%)
Jul 2, 2025, 4:00 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Specialty & Primary Care | 1.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care Growth | 8.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases | 833.86M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Growth | 20.82% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Chemicals | 58.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Chemicals Growth | 11.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 2.28B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 12.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urology and Uro-Oncology | 399.94M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urology and Uro-Oncology Growth | 28.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular | 385.21M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cardiovascular Growth | 7.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gastrointestinal | 217.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gastrointestinal Growth | 2.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cough and Cold | 137.28M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Cough and Cold Growth | -4.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Treatment Areas | 309.31M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Treatment Areas Growth | -0.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Endocrinology | 321.69M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Endocrinology Growth | 28.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Metabolic and Other Areas | 258.94M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Metabolic and Other Areas Growth | 0.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology | 253.23M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Oncology Growth | 37.52% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanidip | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanidip Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanipress | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Zanipress Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urorec | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Urorec Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Livazo | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Livazo Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drugs for Rare Diseases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Drugs for Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Seloken/Logimax | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Seloken/Logimax Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Corporate Products | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Corporate Products Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OTC | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
OTC Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Local Product Portfolios | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Local Product Portfolios Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Eligard | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Eligard Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 2.28B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 12.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 59.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | -15.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care Operating Income | 426.73M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care Operating Income Growth | 4.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Operating Income | 212.13M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Operating Income Growth | 33.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 59.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | -15.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Specialty & Primary Care EBITDA | 524.44M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty & Primary Care EBITDA Growth | 7.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases EBITDA | 341.33M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases EBITDA Growth | 20.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Italy | 336.26M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Italy Growth | 4.43% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International | 2.01B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Growth | 14.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 1.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia and Oceania | 156.01M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Asia and Oceania Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
America | 477.46M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
America Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Africa | 58.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Africa Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Specialty & Primary Care Like-For-Like Growth | 5.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Diseases Like-For-Like Growth | 15.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Like-For-Like Growth | 9.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|